Novartis Seeks 'Amicable' Resolution Of German Probiotics Dispute
Executive Summary
Novartis is in discussion via its Hexal subsidiary with Germany's Association for Social Competition (VSW) over whether it must withdraw its Biosan range of probiotic supplements currently on the German market following a recent Higher Regional Court ruling.
You may also be interested in...
Novartis Wins Second Landmark German Case, This Time For Probiotics
Following a landmark win against the German government for the Rx-to-OTC switch of desloratadine last month, Novartis has again secured a victory in the German Higher Court system, this time to continue marketing its Biosan probiotics range in the country.
Prestige Expands UK Eye Care Range In Response To Consumer Demand
A “great consumer response” to TheraTears in the UK leads Prestige Consumer Healthcare to add TheraTears 5-in-1 Irritation and Redness eye drops to the range.
‘Meaningful Revenues’ In 2023 Mark Strategic Milestone As Futura Looks To Future
Futura recorded its first notable revenues last year, generated by the launch of its Eroxon erectile dysfunction gel in the UK and Europe, marking the company's transition from an R&D startup to a consumer healthcare player in its own right. To mark the occasion, CEO James Barder outlines a new strategy, with a focus on innovation in sexual wellness, further global partnerships and sustained profitability.